Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/22/2023* 17:00 EST Earnings Call Q4 2022 -- -- --
02/22/2023* -- Results Q4 2022 -- -0.83 --
11/03/2022 17:00 EST Earnings Call Q3 2022 -- -- --
11/03/2022 -- Results Q3 2022 -0.74 -1.05 29.23%
08/02/2022 17:00 EST Earnings Call Q2 2022 -- -- --
08/02/2022 -- Results Q2 2022 -0.94 -1.04 10.50%
04/26/2022 17:00 EST Earnings Call Q1 2022 -- -- --
04/26/2022 -- Results Q1 2022 -1.18 -1.04 -13.90%
*Estimated Date/Time

Earnings

Next Report Date 02/22/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/03/2022
Beat/Miss Upgrade
Return Since 43.35%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of the earliest entrants in multi-cancer liquid biopsy cancer screening.
URL https://www.exactsciences.com
Investor Relations URL https://investor.exactsciences.com/investor-relations/default.aspx
HQ State/Province Wisconsin
Sector Healthcare
Industry Diagnostics & Research
Equity Style Mid Cap/Growth
Next Earnings Release Feb. 22, 2023 (est.)
Last Earnings Release Nov. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-66.36%
44.75%
293.3%
20.10%
46.56%
43.26%
-41.26%
-40.43%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-13.26%
--
--
--
--
107.9%
64.93%
-22.39%
-46.20%
3.99%
-33.29%
70.64%
37.27%
10.61%
11.53%
2.82%
-42.50%
--
-3.29%
14.36%
21.81%
45.84%
159.2%
-63.48%
-81.40%
--
--
--
--
--
54.43%
18.78%
-31.10%
As of December 02, 2022.

Profile

Edit
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of the earliest entrants in multi-cancer liquid biopsy cancer screening.
URL https://www.exactsciences.com
Investor Relations URL https://investor.exactsciences.com/investor-relations/default.aspx
HQ State/Province Wisconsin
Sector Healthcare
Industry Diagnostics & Research
Equity Style Mid Cap/Growth
Next Earnings Release Feb. 22, 2023 (est.)
Last Earnings Release Nov. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
ARKG 198.81M USD 9.09%
ARKK 484.83M USD 6.76%
SPYGX 31.81M USD 4.30%
FBT 55.44M USD 3.88%
DYN1628 64.10M USD 2.31%
DYN1798 21.66M USD 2.30%
JACLX 23.62M USD 1.82%
ETCHX 22.79M USD 1.73%
GOFFX 58.48M USD 1.41%
XBI 89.48M USD 1.16%
BBH 5.515M USD 1.09%
LABU 8.372M USD 0.87%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter EXAS Tweets